Herve Affagard

Paradigm breaker Entrepreneur in the Healthcare sector - co-founder and CEO of @MaaT_Pharma #Microbiome

[IACH @TheIACH]

📻𝗜𝗔𝗖𝗛 𝗥𝗮𝗱𝗶𝗼: 𝗢𝗻 𝗔𝗶𝗿 𝗳𝗿𝗼𝗺 #EHA2025

𝘗𝘰𝘰𝘭𝘦𝘥 𝘍𝘦𝘤𝘢𝘭 𝘈𝘭𝘭𝘰𝘨𝘦𝘯𝘪𝘤 𝘔𝘪𝘤𝘳𝘰𝘣𝘪𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘧𝘰𝘳 𝘙𝘦𝘧𝘳𝘢𝘤𝘵𝘰𝘳𝘺 𝘎𝘢𝘴𝘵𝘳𝘰𝘪𝘯𝘵𝘦𝘴𝘵𝘪𝘯𝘢𝘭 𝘈𝘤𝘶𝘵𝘦 𝘎𝘳𝘢𝘧𝘵-𝘷𝘦𝘳𝘴𝘶𝘴-𝘏𝘰𝘴𝘵 𝘋𝘪𝘴𝘦𝘢𝘴𝘦

https://t.co/zbA4bYK8eO

@EHA_Hematology @Mohty_EBMT

[MaaT Pharma @MaaT_Pharma]

Live at #EHA2025 - proud to see Prof. Mohty @Mohty_EBMT presenting promising data for GvHD patients treated with Xervyteg!

[MaaT Pharma @MaaT_Pharma]

📄 [Press release] – MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸

Key highlights:
✅ The independent DSMB has recommended that the study proceed without modification.
✅ Favorable safety profile and tolerability for MaaT033, a standardized pooled donor-derived drug candidate in oral formulation.

Upcoming milestones:
▪ Next DSMB unblinded interim analysis with mortality monitoring scheduled for Q3 2025 at the 120-patient mark.
▪ Routine DSMB review for ongoing safety also expected for Q3 2025.

👉Read the press release here: https://t.co/PpVeNWrBY3

#Hematology #Oncology #BloodCancer #Cancer #DSMB #Safety #Tolerability #Phase2 #Microbiome #Microbiota

[MaaT Pharma @MaaT_Pharma]

📄[Communiqué de presse] – MaaT Pharma annonce le résultat positif de l’analyse intermédiaire de sécurité du DSMB pour l'essai clinique de Phase 2b en cours évaluant MaaT033 pour les patients recevant une allo-GCSH 🩸

Points clés :
✅ Le DSMB a recommandé la poursuite de l'essai sans modification.
✅ Profil de sécurité favorable et une bonne tolérance pour MaaT033, un candidat-médicament standardisé de forme orale développé à partir de plusieurs donneurs.

Prochaines étapes :
· Prochaine analyse intermédiaire après la levée d’aveugle par le DSMB prévue au troisième trimestre 2025, après l’inclusion du 120ème patient.
· Evaluation de sécurité régulière du DSMB aussi attendue pour le troisième trimestre 2025.

👉Lire le communiqué de presse ici : https://t.co/0pchusZbm6

#Oncologie #CancersDuSang #Cancer #DSMB #Sécurité #Tolérabilité #Phase2 #Hématologie #Microbiome #Microbiote

[MaaT Pharma @MaaT_Pharma]

📰 MaaT Pharma in @LePoint!

We’re proud to be featured in the special issue “Ces projets qui façonnent la santé du futur” (Shaping the future of healthcare), written by Valérie Peiffer and Raphaël Ruffier-Fossoul, highlighting our pioneering work in restoring gut microbiome functions to support patients with life-threatening conditions, especially in oncology.

Newspaper available at newsstands or via this link: https://t.co/e6PjHbTgZX

[MaaT Pharma @MaaT_Pharma]

📰 More Great Media Coverage for our positive safety update for MaaT033 in Phase 2b trial!
We’re proud to see @InvestirFr Les Echos cover the DSMB’s favorable interim safety assessment in our ongoing study in allo-HSCT patients.
👉 Read the article here: https://t.co/Rml405SUpN

📰 Nouvelle belle couverture médiatique pour notre actualité sur MaaT033 !
Nous sommes fiers de voir @InvestirFr Les Echos relayer l’analyse intermédiaire de sécurité favorable menée par le DSMB dans le cadre de notre essai clinique de Phase 2b chez les patients recevant une allo-GCSH.
👉Lire l’article ici : https://t.co/Rml405SUpN

#Microbiome #AlloHSCT #ClinicalTrials #MaaT033 #DSMB #Safety #Phase2

[MaaT Pharma @MaaT_Pharma]

📰 #Media - We’re proud to be featured for the first time in Het Financieele Dagblad @FD_Nieuws, a leading Dutch financial daily newspaper,
In an article highlighting the thriving life sciences ecosystem in Lyon, the piece includes our recent clinical milestones, our manufacturing capacities and our regulatory ambitions — all driven by our pioneering work in microbiome science.
We're proud to be included alongside other key institutions and innovative companies helping to shape the future of life sciences: @sanofi @biomerieux @Boehringer @Lyonbiopole @OsivaxVaccines @WHO_Europe

👉 Read the article here: https://t.co/UpOw8qMMQ0

Thank you @OnlyLyon and Florent Gerbaud for the great opportunity.

#Oncology #Biotech #ClinicalTrials #Innovation #Lyon

[MaaT Pharma @MaaT_Pharma]

📄 [Communiqué de Presse] – MaaT Pharma annonce la mise à disposition du Document d’Enregistrement Universel (DEU) 2024

👉 Accéder au document : https://t.co/AT6YDEQN3U

[MaaT Pharma @MaaT_Pharma]

📄 [Press release] – MaaT Pharma Announces the Availability of its 2024 Universal Registration Document (URD)

👉 Access the document: https://t.co/UJwD50TNmr

[MaaT Pharma @MaaT_Pharma]

📢 [#EVENT] - We are proud to share that Bastien Laperrousaz, our Director of Preclinical Development, will be presenting at the American Association for Cancer Research @AACR Annual Meeting 2025. He will comment on promising preclinical data for MaaT034, our synthetic microbiome therapy, designed to improve patients’ responses to immunotherapies.
📅 April 25-30, 2025
📍 Chicago, Illinois

Stay tuned for more on how microbiome modulation could support the future of cancer care.

#AACR2025 #Immunotherapies #Microbiome #Cancer #Oncology #Innovation #Research #Preclinical

[Herve Affagard @HAffagard]

@EmmanuelMacron @EmmanuelMacron - En tant que "patron" je suggère aussi que l'on mette beaucoup d'enegergie pour créer un environnement business friendly en Europe (Reglementation, marchés boursiers, etc...).

[MaaT Pharma @MaaT_Pharma]

💡 [#WorldCancerDay 2025] - There’s never been a more exciting time in #microbiome #research, especially in #oncology. We’re proud that our ARES trial is contributing to the field, and to a potential breakthrough treatment.
Learn more from Professor @Mohty_EBMT on what it could mean for #patients.

#Oncology #Hematology #aGvHD #Cancer

[MaaT Pharma @MaaT_Pharma]

📰 - MaaT Pharma in Bloomberg @business - We’re proud to see our work featured in Bloomberg, spotlighting the potential of microbiome therapy in cancer care. The article and film share the inspiring patient’s story, who overcame aGvHD, a life-threatening complication after a stem-cell transplant, and includes a testimonial from Dr. Loschi, who treated her through the Early Access Program.

Thank you to Jason Gale @jwgale for writting avout the potential of microbiome-based therapies beyond infectious diseases.

🔗 Read the full Bloomberg article: https://t.co/6biPi0iVUV
🔗 Watch the video on Bloomberg Originals: https://t.co/ch6IUjHtao

#Bloomberg
#MicrobiomeTherapy #CancerCareInnovation #GVHD #Microbiome #Hematology #Oncology #JPM2025

[MTIG @MTIG_News]

.@MaaT_Pharma 's MaaT013 has the potential to be the first approved third-line treatment option & transform the survival outcomes and redefine long-term prospects for approximately 3,000 third-line GI-aGvHD patients per year in the U.S., Canada & Europe. https://t.co/azTScPqhok

[MaaT Pharma @MaaT_Pharma]

📄[Press release] – MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT🩸
https://t.co/GOpziUXFrG

#Microbiome #BloodCancer #Cancer #DSMB #Safety #Tolerability #Phase2

[MaaT Pharma @MaaT_Pharma]

📄[Communiqué de presse] – MaaT Pharma annonce le résultat positif du deuxième DSMB pour l'essai clinique de Phase 2b en cours évaluant MaaT033 pour les patients recevant une allo-GCSH 🩸
👉https://t.co/wyUQLBdt5L

#Microbiote #CancersDuSang #Cancer #DSMB #Sécurité #Tolérabilité #Phase2

[Herve Affagard @HAffagard]

Steep streets of #SanFrancisco are like the entrepreneur's journey: full of uphill climbs, unexpected turns, and rewarding views at the top. No exception during #JPM2025, every climb leads to a breathtaking view. 🚋✨ #Entrepreneurship #GoodVibes @MaaT_Pharma

[Herve Affagard @HAffagard]

Steep streets of #SanFrancisco are like the entrepreneur's journey: full of uphill climbs, unexpected turns, and rewarding views at the top. No exception during #JPM2025, every climb leads to a breathtaking view. 🚋✨ #Entrepreneurship #GoodVibes @MaaT_Pharma

[Herve Affagard @HAffagard]

@MaaT_Pharma @herve @FierceBiotech @RebeccaEFriend Thank you @RebeccaEFriend

[MaaT Pharma @MaaT_Pharma]

🎥 Behind the scenes in San Francisco! MaaT Pharma’s CEO, @Herve Affagard @HAffagard sat down today with @FierceBiotech 's Rebecca Willumson @RebeccaEFriend during #JPM2025 for an exclusive interview. They discussed our exciting Phase 3 ARES data announcement and what’s ahead for MaaT Pharma in 2025.

Stay tuned—the full video will be shared in the coming weeks.

#Cancer #Oncology #MicrobiomeInnovation #Biotech #HealthcareTransformation